Real-world clinical evidence platform for drug efficacy and safety studies
Target RWE aggregates longitudinal health-system data to generate clinical evidence for pharmaceutical and biotech sponsors. The stack reflects a mature data engineering operation: Epic/Cerner connectors, FHIR/HL7 data pipelines, R/Python analytics, Spark/Dask distributed processing, and multi-cloud infrastructure (AWS/GCP/Azure). Hiring is heavily skewed toward data roles (11 of 19 open positions), with nearly all at senior and lead levels—a pattern that signals scaling data ingestion and validation challenges. Recent acquisition by Highlander Health (January 2025) is expanding capacity to run prospective studies alongside retrospective analysis.
Notable leadership hires: Science Head, Project Lead
Target RWE builds infrastructure for real-world evidence generation, partnering with health systems and key opinion leaders to produce clinical data products in hepatology, gastroenterology, and dermatology. The platform ingests longitudinal patient records from EHR systems, applies epidemiological methods to derive safety and efficacy insights, and supports both retrospective data analysis and prospective clinical trial enrollment. The company operates a multi-stakeholder model: health systems provide data access, research partners design studies, and commercial sponsors fund evidence generation. Founded in 2015 and based in Durham, North Carolina, Target RWE now operates under Highlander Health's ownership.
Core tools: Epic/Cerner EHR connectors, FHIR/HL7 data standards, R and Python for analytics, Apache Spark/Dask for distributed processing, PostgreSQL for storage, AWS/GCP/Azure for cloud infrastructure, and Salesforce for business operations.
Currently active in hepatology (NASH, HCC, chronic hepatitis B), gastroenterology (IBD, PBC), and dermatology (immune-mediated inflammatory skin conditions, asthma). The company plans to expand into additional therapeutic areas.
Other companies in the same industry, closest in size